Halozyme Therapeutic (HALO) 12.43 $HALO Uptrend
Post# of 273254
Posted On: 09/22/2016 5:14:58 AM
Halozyme Therapeutic (HALO) 12.43 $HALO
Uptrend Call Working As Halozyme Therapeutics Stock Rises 15.8% (HALO)
Comtex SmarTrend(R) - Wed Sep 21, 1:46PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on August 4th, 2016 at $10.38. In approximately 2 months, Halozyme Therapeutics has returned 15.76% as of today's recent price of $12.01.
HALO: 12.43 (-0.07)
Watch for Halozyme Therapeutics to Potentially Pullback After Gaining 5.05% Yesterday
Comtex SmarTrend(R) - Tue Sep 20, 3:43PM CDT
Halozyme Therapeutics (NASDAQ:HALO) traded in a range yesterday that spanned from a low of $12.13 to a high of $12.75. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $12.28 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HALO: 12.43 (-0.07)
Halozyme Therapeutics (HALO) Catches Eye: Stock Up 7.9%
Zacks Equity Research - Zacks Investment Research - Mon Sep 19, 7:40AM CDT
Halozyme Therapeutics, Inc. (HALO) saw its shares rise almost 8% in the last trading session.
HALO: 12.43 (-0.07), ANIP: 65.12 (+0.28)
Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Global Health Care Conference
PR Newswire - Thu Sep 08, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Bank of America Merrill Lynch 2016 Global Health Care Conference in London, on Thurs., Sept. 15 at 11:25 a.m. BST/6:25 a.m. EDT/3:25 a.m. PDT. Dr. Helen Torley, president and CEO, will provide a corporate overview.
HALO: 12.43 (-0.07)
Halozyme Names Mark J. Gergen As Chief Operating Officer
PR Newswire - Thu Sep 01, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech developing novel oncology and drug-delivery therapies, today named biotech veteran Mark J. Gergen as senior vice president and chief operating officer, reporting to Dr. Helen Torley, president and chief executive officer.
HALO: 12.43 (-0.07)
Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
PR Newswire - Wed Aug 31, 3:15PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Wells Fargo Healthcare Conference in Boston on Weds., Sept. 7 at 4:05 p.m. ET/1:05 p.m. PT. and at the Baird Global Healthcare Conference in New York on Thurs., Sept. 8 at 1:25 p.m. ET/10:25 a.m. PT. Dr. Helen Torley, president and CEO, will represent the company at both conferences.
HALO: 12.43 (-0.07), WFC: 45.83 (-0.73)
Research Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and Chimerix
PR Newswire - Tue Aug 23, 6:40AM CDT
Biotechnology harnesses cellular and biomolecular processes to develop technologies and products, which include food technology, genetic research, healthcare, and environmental technology. Equities under assessment on Stock-Callers.com today are: Halozyme Therapeutics Inc. (NASDAQ: HALO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Chimerix Inc. (NASDAQ: CMRX). These stocks research reports can be downloaded now by simply registering for free at:
HALO: 12.43 (-0.07), CMRX: 5.84 (-0.02), ACHN: 8.10 (+0.14), AEGR: 2.32 (-0.05)
Halozyme Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results and recent highlights for the second quarter ended June 30.
HALO: 12.43 (-0.07)
Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance
PR Newswire - Wed Jun 08, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has entered into an agreement with Oxford Finance LLC and Silicon Valley Bank to refinance its existing senior secured loan facility.
HALO: 12.43 (-0.07)
Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20
PR Newswire - Sat Jun 04, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced results from a final analysis of 135 metastatic pancreatic cancer patients who were treated in Stage One of HALO 109-202, a phase 2 clinical study of its investigational new drug PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine (PAG arm) as compared to ABRAXANE and gemcitabine alone (AG arm).
HALO: 12.43 (-0.07)
Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference
PR Newswire - Tue May 17, 3:15PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2016 Global Health Care Conference in New York, on Tuesday, May 24 at 2:30 p.m. ET/11:30 a.m. PT. Laurie Stelzer, chief financial officer, will provide a corporate overview.
HALO: 12.43 (-0.07)
Halozyme Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 3:37PM CDT
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $19.8 million in its first quarter.
HALO: 12.43 (-0.07)
Halozyme Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 09, 3:05PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, which included an increase in revenue of 128 percent from the prior-year period and a net loss of $19.8 million, or $0.16 per share, compared to a net loss in the first quarter of 2015 of $15.1 million, or $0.12 per share.
HALO: 12.43 (-0.07)
The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma
Zacks Equity Research - Zacks Investment Research - Mon May 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma
HALO: 12.43 (-0.07), KITE: 55.58 (-0.10), INCY: 86.71 (+1.65), HZNP: 19.17 (+0.26), JUNO: 31.32 (+1.57)
Biotech Stocks Reporting on May 9: INCY, HZNP, JUNO & More
Kanchan Khanna - Zacks Investment Research - Fri May 06, 8:52AM CDT
What's in store for biotech stocks Juno, Incyte and others when they report their first-quarter results on May 9?
HALO: 12.43 (-0.07), KITE: 55.58 (-0.10), MDCO: 40.96 (+1.11), INCY: 86.71 (+1.65), HZNP: 19.17 (+0.26), AMGN: 173.85 (+0.47), JUNO: 31.32 (+1.57)
Halozyme Therapeutics Shares Up 31.1% Since SmarTrend's Buy Recommendation (HALO)
Comtex SmarTrend(R) - Fri Apr 22, 1:01PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on March 1st, 2016 at $9.07. In approximately 2 months, Halozyme Therapeutics has returned 31.11% as of today's recent price of $11.89.
HALO: 12.43 (-0.07)
Halozyme to Host First Quarter 2016 Financial Results Conference Call
PR Newswire - Wed Apr 20, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter on Monday, May 9 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2016.
HALO: 12.43 (-0.07)
Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment
PR Newswire - Mon Apr 18, 3:01PM CDT
Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced preclinical data for the discovery and early development of two potential drug candidates, an immune checkpoint inhibitor targeting adenosine and a novel antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR).
HALO: 12.43 (-0.07)
Uptrend Call Working As Halozyme Therapeutics Stock Rises 15.8% (HALO)
Comtex SmarTrend(R) - Wed Sep 21, 1:46PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on August 4th, 2016 at $10.38. In approximately 2 months, Halozyme Therapeutics has returned 15.76% as of today's recent price of $12.01.
HALO: 12.43 (-0.07)
Watch for Halozyme Therapeutics to Potentially Pullback After Gaining 5.05% Yesterday
Comtex SmarTrend(R) - Tue Sep 20, 3:43PM CDT
Halozyme Therapeutics (NASDAQ:HALO) traded in a range yesterday that spanned from a low of $12.13 to a high of $12.75. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $12.28 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HALO: 12.43 (-0.07)
Halozyme Therapeutics (HALO) Catches Eye: Stock Up 7.9%
Zacks Equity Research - Zacks Investment Research - Mon Sep 19, 7:40AM CDT
Halozyme Therapeutics, Inc. (HALO) saw its shares rise almost 8% in the last trading session.
HALO: 12.43 (-0.07), ANIP: 65.12 (+0.28)
Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2016 Global Health Care Conference
PR Newswire - Thu Sep 08, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Bank of America Merrill Lynch 2016 Global Health Care Conference in London, on Thurs., Sept. 15 at 11:25 a.m. BST/6:25 a.m. EDT/3:25 a.m. PDT. Dr. Helen Torley, president and CEO, will provide a corporate overview.
HALO: 12.43 (-0.07)
Halozyme Names Mark J. Gergen As Chief Operating Officer
PR Newswire - Thu Sep 01, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), an oncology biotech developing novel oncology and drug-delivery therapies, today named biotech veteran Mark J. Gergen as senior vice president and chief operating officer, reporting to Dr. Helen Torley, president and chief executive officer.
HALO: 12.43 (-0.07)
Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
PR Newswire - Wed Aug 31, 3:15PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will be presenting at the Wells Fargo Healthcare Conference in Boston on Weds., Sept. 7 at 4:05 p.m. ET/1:05 p.m. PT. and at the Baird Global Healthcare Conference in New York on Thurs., Sept. 8 at 1:25 p.m. ET/10:25 a.m. PT. Dr. Helen Torley, president and CEO, will represent the company at both conferences.
HALO: 12.43 (-0.07), WFC: 45.83 (-0.73)
Research Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and Chimerix
PR Newswire - Tue Aug 23, 6:40AM CDT
Biotechnology harnesses cellular and biomolecular processes to develop technologies and products, which include food technology, genetic research, healthcare, and environmental technology. Equities under assessment on Stock-Callers.com today are: Halozyme Therapeutics Inc. (NASDAQ: HALO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Chimerix Inc. (NASDAQ: CMRX). These stocks research reports can be downloaded now by simply registering for free at:
HALO: 12.43 (-0.07), CMRX: 5.84 (-0.02), ACHN: 8.10 (+0.14), AEGR: 2.32 (-0.05)
Halozyme Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results and recent highlights for the second quarter ended June 30.
HALO: 12.43 (-0.07)
Halozyme Announces Agreement To Refinance Debt, Increases 2016 Guidance For Year-End Cash Balance
PR Newswire - Wed Jun 08, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that it has entered into an agreement with Oxford Finance LLC and Silicon Valley Bank to refinance its existing senior secured loan facility.
HALO: 12.43 (-0.07)
Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20
PR Newswire - Sat Jun 04, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced results from a final analysis of 135 metastatic pancreatic cancer patients who were treated in Stage One of HALO 109-202, a phase 2 clinical study of its investigational new drug PEGPH20 in combination with ABRAXANE (nab-paclitaxel) and gemcitabine (PAG arm) as compared to ABRAXANE and gemcitabine alone (AG arm).
HALO: 12.43 (-0.07)
Halozyme Therapeutics To Present At The UBS 2016 Global Health Care Conference
PR Newswire - Tue May 17, 3:15PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the UBS 2016 Global Health Care Conference in New York, on Tuesday, May 24 at 2:30 p.m. ET/11:30 a.m. PT. Laurie Stelzer, chief financial officer, will provide a corporate overview.
HALO: 12.43 (-0.07)
Halozyme Therapeutics reports 1Q loss
Automated Insights - Mon May 09, 3:37PM CDT
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $19.8 million in its first quarter.
HALO: 12.43 (-0.07)
Halozyme Reports First Quarter 2016 Financial Results
PR Newswire - Mon May 09, 3:05PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the first quarter ended March 31, which included an increase in revenue of 128 percent from the prior-year period and a net loss of $19.8 million, or $0.16 per share, compared to a net loss in the first quarter of 2015 of $15.1 million, or $0.12 per share.
HALO: 12.43 (-0.07)
The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma
Zacks Equity Research - Zacks Investment Research - Mon May 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma
HALO: 12.43 (-0.07), KITE: 55.58 (-0.10), INCY: 86.71 (+1.65), HZNP: 19.17 (+0.26), JUNO: 31.32 (+1.57)
Biotech Stocks Reporting on May 9: INCY, HZNP, JUNO & More
Kanchan Khanna - Zacks Investment Research - Fri May 06, 8:52AM CDT
What's in store for biotech stocks Juno, Incyte and others when they report their first-quarter results on May 9?
HALO: 12.43 (-0.07), KITE: 55.58 (-0.10), MDCO: 40.96 (+1.11), INCY: 86.71 (+1.65), HZNP: 19.17 (+0.26), AMGN: 173.85 (+0.47), JUNO: 31.32 (+1.57)
Halozyme Therapeutics Shares Up 31.1% Since SmarTrend's Buy Recommendation (HALO)
Comtex SmarTrend(R) - Fri Apr 22, 1:01PM CDT
SmarTrend identified an Uptrend for Halozyme Therapeutics (NASDAQ:HALO) on March 1st, 2016 at $9.07. In approximately 2 months, Halozyme Therapeutics has returned 31.11% as of today's recent price of $11.89.
HALO: 12.43 (-0.07)
Halozyme to Host First Quarter 2016 Financial Results Conference Call
PR Newswire - Wed Apr 20, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter on Monday, May 9 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2016.
HALO: 12.43 (-0.07)
Halozyme Expands Oncology Pipeline With Two Compounds Designed For Activity In The Tumor Microenvironment
PR Newswire - Mon Apr 18, 3:01PM CDT
Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced preclinical data for the discovery and early development of two potential drug candidates, an immune checkpoint inhibitor targeting adenosine and a novel antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR).
HALO: 12.43 (-0.07)
(0)
(0)Scroll down for more posts ▼